0
Skip to Content
Rejuvenate Bio
Home
Team
Advisory Board
Investors
Partners
Our Science
Pipeline
MVD Trial 2020
MVD Trial 2026
Press Releases
In the News
Contact Us
Invest in Rejuvenate
Rejuvenate Bio
Home
Team
Advisory Board
Investors
Partners
Our Science
Pipeline
MVD Trial 2020
MVD Trial 2026
Press Releases
In the News
Contact Us
Invest in Rejuvenate
Home
Folder: About Us
Back
Team
Advisory Board
Investors
Partners
Our Science
Pipeline
Folder: Trials
Back
MVD Trial 2020
MVD Trial 2026
Folder: Press
Back
Press Releases
In the News
Contact Us
Invest in Rejuvenate

Phibro Animal Health Corporation and Rejuvenate Bio Announce Agreement to Develop Gene Therapy for Mitral Valve Disease in Canines

Jul 18
Written by Noah Davidsohn
Noah Davidsohn
Previous
Previous

Rejuvenate Bio Announces Team Expansion with Appointments of Garrett Berry and Sophia Gee

Next
Next

Rejuvenate Bio Raises Over $10M in Series A Funding for Gene Therapy Aging Treatment

Rejuvenate_Logo_PNG_Blue.png
 

Home Page

Our Science

Pipeline

Press Releases

In the News

Terms & Conditions

Team

Careers

Contact Us